Atomistry » Sodium » PDB 7z05-7zkm » 7zi7
Atomistry »
  Sodium »
    PDB 7z05-7zkm »
      7zi7 »

Sodium in PDB 7zi7: Crystal Structure of Dck C4S-S74E Mutant in Complex with Udp and the OR0345 Inhibitor

Enzymatic activity of Crystal Structure of Dck C4S-S74E Mutant in Complex with Udp and the OR0345 Inhibitor

All present enzymatic activity of Crystal Structure of Dck C4S-S74E Mutant in Complex with Udp and the OR0345 Inhibitor:
2.7.1.113; 2.7.1.74; 2.7.1.76;

Protein crystallography data

The structure of Crystal Structure of Dck C4S-S74E Mutant in Complex with Udp and the OR0345 Inhibitor, PDB code: 7zi7 was solved by M.Saez-Ayala, K.Ben-Yaala, S.Betzi, E.Rebuffet, X.Morelli, with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:

Resolution Low / High (Å) 48.53 / 1.80
Space group P 41 2 2
Cell size a, b, c (Å), α, β, γ (°) 68.627, 68.627, 120.601, 90, 90, 90
R / Rfree (%) 18.7 / 22.7

Sodium Binding Sites:

The binding sites of Sodium atom in the Crystal Structure of Dck C4S-S74E Mutant in Complex with Udp and the OR0345 Inhibitor (pdb code 7zi7). This binding sites where shown within 5.0 Angstroms radius around Sodium atom.
In total only one binding site of Sodium was determined in the Crystal Structure of Dck C4S-S74E Mutant in Complex with Udp and the OR0345 Inhibitor, PDB code: 7zi7:

Sodium binding site 1 out of 1 in 7zi7

Go back to Sodium Binding Sites List in 7zi7
Sodium binding site 1 out of 1 in the Crystal Structure of Dck C4S-S74E Mutant in Complex with Udp and the OR0345 Inhibitor


Mono view


Stereo pair view

A full contact list of Sodium with other atoms in the Na binding site number 1 of Crystal Structure of Dck C4S-S74E Mutant in Complex with Udp and the OR0345 Inhibitor within 5.0Å range:
probe atom residue distance (Å) B Occ
A:Na303

b:40.1
occ:1.00
O A:TRP48 2.2 40.5 1.0
O A:LYS42 2.3 40.9 1.0
O A:SER45 2.3 43.2 1.0
O A:HOH401 2.4 54.1 1.0
O A:HOH484 2.4 49.4 1.0
C A:TRP48 3.4 34.7 1.0
C A:LYS42 3.4 39.0 1.0
C A:SER45 3.5 50.8 1.0
CA A:LYS42 4.0 40.9 1.0
CA A:GLU46 4.1 48.4 1.0
N A:TRP48 4.1 38.3 1.0
CA A:TRP48 4.1 34.3 1.0
N A:GLU46 4.2 44.0 1.0
CB A:TRP48 4.3 35.8 1.0
OE1 A:GLU49 4.3 61.2 1.0
C A:GLU46 4.3 44.4 1.0
N A:SER45 4.4 39.5 1.0
CB A:LYS42 4.5 43.6 1.0
N A:GLU49 4.5 37.5 1.0
O A:GLU46 4.5 49.0 1.0
N A:GLN43 4.5 40.9 1.0
CA A:SER45 4.6 42.7 1.0
CD A:GLU49 4.7 58.0 1.0
CA A:GLU49 4.8 38.6 1.0
OE2 A:GLU49 4.9 67.6 1.0
N A:ASP47 4.9 38.7 1.0
CA A:GLN43 4.9 42.6 1.0
O A:LEU41 5.0 37.1 1.0

Reference:

M.Saez-Ayala, L.Hoffer, S.Abel, K.Ben Yaala, B.Sicard, G.P.Andrieu, M.Latiri, E.K.Davison, M.A.Ciufolini, P.Bremond, E.Rebuffet, P.Roche, C.Derviaux, E.Voisset, C.Montersino, R.Castellano, Y.Collette, V.Asnafi, S.Betzi, P.Dubreuil, S.Combes, X.Morelli. From A Drug Repositioning to A Structure-Based Drug Design Approach to Tackle Acute Lymphoblastic Leukemia. Nat Commun V. 14 3079 2023.
ISSN: ESSN 2041-1723
PubMed: 37248212
DOI: 10.1038/S41467-023-38668-2
Page generated: Mon Aug 18 12:51:13 2025

Last articles

Mn in 9LJU
Mn in 9LJW
Mn in 9LJS
Mn in 9LJR
Mn in 9LJT
Mn in 9LJV
Mg in 9UA2
Mg in 9R96
Mg in 9VM1
Mg in 9P01
© Copyright 2008-2020 by atomistry.com
Home   |    Site Map   |    Copyright   |    Contact us   |    Privacy